HARROW INC: ENVISIONING A BRIGHT FUTURE$HROW Excited to share an article about Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market.
In FY23, Harrow achieved a 70% gross margin and a 47% increase in revenues YoY. For FY24, the Company has provided guidance of at least $180 million in revenues, which indicates a 38% increase over FY23 revenues.
Over the last few years, Harrow's revenues have climbed steadily upwards, and it seems that this trend will continue in the future - this makes the Company an interesting watch.
Read on to know more: https://www.aviseanalytics.com/harrow-inc-envisioning-a-bright-future/